Patents by Inventor Yubin Qiu

Yubin Qiu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
    Patent number: 11524998
    Abstract: The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.
    Type: Grant
    Filed: July 14, 2021
    Date of Patent: December 13, 2022
    Assignee: NOVARTIS AG
    Inventors: Chad Eric Bigelow, Ana Maria Carrion, James Edgar Chastain, Kirk Lee Clark, Bijan Alexandre Etemad-Gilbertson, Joy Gispati Ghosh, Shawn Michael Hanks, Nicole Haubst, Ganesh Rajan Iyer, Nina Moker, Andrew Anh Nguyen, Stephen Hedrick Poor, Yubin Qiu, Nalini Velamur Rangaswamy, Michael Stefanidakis, Engin Toksoz, Michael Zbigniew Twarog
  • ANTI-BETACELLULIN ANTIBODIES, FRAGMENTS THEREOF, AND MULTI-SPECIFIC BINDING MOLECULES
    Publication number: 20220356236
    Abstract: The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.
    Type: Application
    Filed: June 30, 2022
    Publication date: November 10, 2022
    Inventors: Chad Eric BIGELOW, Ana Maria CARRION, James Edgar CHASTAIN, Kirk Lee CLARK, Bijan Alexandre ETEMAD-GILBERTSON, Joy Gispati GHOSH, Shawn Michael HANKS, Nicole HAUBST, Ganesh Rajan IYER, Nina MOKER, Andrew Anh NGUYEN, Stephen Hendrick POOR, Yubin QIU, Nalini Velamur RANGASWAMY, Michael STEFANIDAKIS, Engin TOKSOZ, Michael Zbigniew TWAROG
  • ANTI-BETACELLULIN ANTIBODIES, FRAGMENTS THEREOF, AND MULTI-SPECIFIC BINDING MOLECULES
    Publication number: 20220348646
    Abstract: The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.
    Type: Application
    Filed: June 30, 2022
    Publication date: November 3, 2022
    Inventors: Chad Eric BIGELOW, Ana Maria CARRION, James Edgar CHASTAIN, Kirk Lee CLARK, Bijan Alexandre ETEMAD-GILBERTSON, Joy Gispati GHOSH, Shawn Michael HANKS, Nicole HAUBST, Ganesh Rajan IYER, Nina MOKER, Andrew Anh NGUYEN, Stephen Hendrick POOR, Yubin QIU, Nalini Velamur RANGASWAMY, Michael STEFANIDAKIS, Engin TOKSOZ, Michael Zbigniew TWAROG
  • ANTI-BETACELLULIN ANTIBODIES, FRAGMENTS THEREOF, AND MULTI-SPECIFIC BINDING MOLECULES
    Publication number: 20220025032
    Abstract: The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.
    Type: Application
    Filed: July 14, 2021
    Publication date: January 27, 2022
    Inventors: Chad Eric BIGELOW, Ana Maria CARRION, James Edgar CHASTAIN, Kirk Lee CLARK, Bijan Alexandre ETEMAD-GILBERTSON, Joy Gispati GHOSH, Shawn Michael HANKS, Nicole HAUBST, Ganesh Rajan IYER, Nina MOKER, Andrew Anh NGUYEN, Stephen Hendrick POOR, Yubin QIU, Nalini Velamur RANGASWAMY, Michael STEFANIDAKIS, Engin TOKSOZ, Michael Zbigniew TWAROG
  • DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE
    Publication number: 20130197016
    Abstract: The use of vascular endothelial growth factor receptor 2 inhibitors or a pharmaceutically acceptable salt thereof for the treatment of ocular vascular disease is provided. Dosing regimes, including once weekly administration, of certain VEGF-R2 inhibitors are provided which deliver therapeutically effective concentrations of the VEGF-R2 compounds in ocular tissues for at least one week for the treatment of ocular vascular disease.
    Type: Application
    Filed: October 25, 2011
    Publication date: August 1, 2013
    Inventors: Mitchell Brigell, Peter End, Vinayak Hosagrahara, Bruce D. Jaffee, Erik Meredith, Ronald Keith Newton, Stephen Poor, Yubin Qiu